CervoMed (CRVO) Notes Payables (2010 - 2022)

CervoMed (CRVO) posted Notes Payables of $12.4 million for Q4 2022, down 23.92% sequentially from $16.3 million in Q3 2017.

CervoMed (CRVO) Notes Payables (2010 - 2022) Analysis & Trends

CervoMed has reported Notes Payables for 7 years, with the latest figure at $12.4 million in Q4 2022.

Quarterly Notes Payables changed N/A year-over-year to $12.4 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $12.4 million (changed N/A YoY) and the FY2022 annual result came in at $12.4 million, changed N/A from the prior year.
Notes Payables fell to $12.4 million in Q4 2022 per CRVO's latest filing, from $16.3 million in the prior quarter.
Over five years, Notes Payables peaked at $12.4 million in Q4 2022 and troughed at $12.4 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.76 Bn	130.91 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	86.15 Bn	78.15 Bn	3.93 Bn
3	Argenx Se	64.45 Bn	59.27 Bn	1.37 Bn
4	Moderna	57.08 Bn	51.94 Bn	52.00 Mn
5	BeOne Medicines	42.08 Bn	36.99 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.90 Bn	27.59 Bn	992.69 Mn
7	BioNTech SE	27.76 Bn	9.37 Bn	668.28 Mn
8	Insmed	27.45 Bn	26.29 Bn	358.27 Mn
9	Royalty Pharma	27.00 Bn	26.17 Bn	-
10	CervoMed	26.94 Mn	26.94 Mn	-

Download Data